FORM 8.1(a) & (b) (Disclosure of Initial Position)
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: Nov 05 20250mins
Disclosure Overview: Alkermes plc has made a disclosure under the Irish Takeover Panel Act regarding its position as the offeror in relation to Avadel Pharmaceuticals plc, with the latest position held as of November 3, 2025.
Interests and Positions: The disclosure includes details of interests and short positions, indicating that there are no significant interests or positions to report beyond those of J.P. Morgan, which holds a minor percentage of shares.
No Inducements or Agreements: The disclosure states that there are no indemnity arrangements or agreements that may influence dealings in the relevant securities.
Contact Information: The disclosure was made public on November 5, 2025, with Sandy Coombs as the contact person for further inquiries, providing a telephone number for communication.
ALKS.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ALKS
Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 43.33 USD with a low forecast of 34.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 29.040
Low
34.00
Averages
43.33
High
50.00
Current: 29.040
Low
34.00
Averages
43.33
High
50.00
Deutsche Bank
David Hoang
Buy
downgrade
$55 -> $45
2025-11-13
New
Reason
Deutsche Bank
David Hoang
Price Target
$55 -> $45
2025-11-13
New
downgrade
Buy
Reason
Deutsche Bank analyst David Hoang lowered the firm's price target on Alkermes to $45 from $55 and keeps a Buy rating on the shares. The company announced positive topline data from its Phase 2 VIBRANCE-2 trial of alixorexton in narcolepsy type 2, but results came in below the high expectations needed for the drug to be a "clear best-in-class therapy," the analyst tells investors in a research note. The firm believes the shares dropped yesterday on a perceived less competitive commercial profile for alixorexton versus peers.
Truist
Joon Lee
Buy
maintain
$50
2025-11-12
Reason
Truist
Joon Lee
Price Target
$50
2025-11-12
maintain
Buy
Reason
Truist analyst Joon Lee says that while Alkermes announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study evaluating alixorexton in patients with narcolepsy type 2, the "details are scant." Truist is "comforted" that 95% of patients chose to enter the optional five-week open-label extension, which it believes speaks to a good benefit/risk ratio. The firm has a Buy rating on Alkermes with a $50 price target. The stock in morning trading is down 12%, or $3.94, to $29.88.
Evercore ISI
Evercore ISI
Outperform
maintain
$30.47
2025-11-12
Reason
Evercore ISI
Evercore ISI
Price Target
$30.47
2025-11-12
maintain
Outperform
Reason
Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the "Street has had a confused reaction to all the new data out of Alkermes and Centessa recently." While the Street thinks the company missed the 20 minute MWT within the arm or greater than 10 minute MWT bar versus placebo, the firm contends "they didn't" and added that Alkermes avoided the "disaster scenario" of failing in narcolepsy type 2 like Takeda's (TAK) TAK-861. The firm, which thinks the Street is "grossly underestimating the clinician interest in this category for narcolepsy," has an Outperform rating on Alkermes shares, which are down $3.34, or 10% to $30.47 in morning trading.
BofA
Jason Gerberry
Neutral
maintain
$33 -> $34
2025-10-28
Reason
BofA
Jason Gerberry
Price Target
$33 -> $34
2025-10-28
maintain
Neutral
Reason
BofA analyst Jason Gerberry raised the firm's price target on Alkermes to $34 from $33 and keeps a Neutral rating on the shares following what the firm calls "a good beat/raise 3Q." While Q3 results were "solid," the firm continues to see the upcoming Vibrance-2 readout in narcolepsy type-2 in November as "a stock driver," says the analyst, who raised the firm's FY25 and onward topline estimates by 1%-2% given strength in the base business.
See All Ratings
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of Alkermes' disclosure under the Irish Takeover Panel Act?
Why does the disclosure highlight J.P. Morgan's minor percentage of shares?
How might Alkermes' position as an offeror impact Avadel Pharmaceuticals' future?
What are the potential outcomes for investors holding the January 2028 options?